Joincare(SH:600380) Ge Long Hui A P P·2025-12-21 07:52Core Viewpoint - The announcement indicates that the company's subsidiary, Lizhu Pharmaceutical Factory, has received approval from the National Medical Products Administration for clinical trials of NS-041 tablets, which are aimed at treating depression and epilepsy, marking a significant development in the field of neuropsychiatric disorders [1] Group 1 - The NS-041 tablet is a novel high-selectivity KCNQ2/3 agonist, targeting both epilepsy and depression, making it the only KCNQ2/3 targeted drug in China approved for clinical research in both conditions [1] - As of the announcement date, there are no new generation targeted KCNQ2/3 drugs available in the domestic market [1] - Following the approval for clinical trials, the drug must still undergo clinical testing and receive further review and approval from the National Medical Products Administration before it can be manufactured and marketed, indicating several uncertainties ahead [1]